Trial Profile
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Bavunalimab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Male breast cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Penile cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions
- Acronyms DUET-4
- Sponsors Xencor
- 29 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 May 2022 Status changed from recruiting to active, no longer recruiting.
- 03 May 2021 Planned End Date changed from 1 Mar 2027 to 1 Nov 2025.